Metabolomics Market Size, Share & Industry Analysis, By Offering (Products {Instruments and Consumables}, Software, and Services), By Technique (Liquid Chromatography-Mass Spectrometry (LC-MS), Gas Chromatography-Mass Spectrometry (GC-MS), Nuclear Magnetic Resonance Spectroscopy (NMR), and Others), By Application (Biomarker Discovery, Drug Discovery, Toxicology Testing, & Others), By Disease Indication (Cancer, Cardiovascular Diseases, Neurological Disorders, & Others), By End User (Pharmaceutical and Biotechnology Companies, CROs / CMOs, & Others), and Regional Forecast, 2026-2034

The global metabolomics market size was valued at USD 2.29 billion in 2025. The market is projected to grow from USD 2.52 billion in 2026 to USD 6.26 billion by 2034, exhibiting a CAGR of 12.07% during the forecast period.

The global market is anticipated to grow exponentially in the coming years due to advances in proteomics and genomics research. Metabolomics provides an overview of metabolite levels, showcasing how metabolic flow through various pathways in response to stimuli. These platforms also offer advances in analytical capabilities. The widespread application of the study in proteomics and genomics research and biomarker discovery further fuels growth.

Furthermore, innovative techniques and technologies that deliver more sensitive results drive market growth.     

• For instance, in May 2025, Bruker launched a novel time-of-flight mass spectrometer for breakthrough 4D-metabolomics and 4D-lipidomics, with sensitivity, specificity, and annotation confidence. Such developments are anticipated to boost the overall market growth.

Furthermore, leading players in the industry, such as Merck KGaA and DH Life Sciences, LLC, are directing their resources toward research and development, expanding their offerings, and strengthening their market positions.

METABOLOMICS MARKET TRENDS

AI Integration in Bioinformatics Tools is a Significant Market Trend Observed

A significant global market trend is the shift toward automated bioinformatics platforms. Metabolomics datasets are expanding and becoming larger and more complex. Traditional workflows, such as exporting files, manual cleaning, scripting, and back-and-forth with bioinformaticians, increase the risk of inconsistent analysis as study sizes and the need for a single workspace where users can quickly run standard workflows increase. This shift toward automated bioinformatics tools overcomes these challenges, reducing turnaround time, improving repeatability across projects, and making metabolomics easier to scale. Underscoring these advantages, many key companies are increasingly investing in these solutions and advancing their bioinformatics platforms.  

• For instance, in September 2024, Metabolon, Inc., a provider of metabolomics solutions, launched an advanced statistical analysis tool within the company’s bioinformatics platform. Such developments are expected to boost market growth.

Download Free sample to learn more about this report.

MARKET DYNAMICS

MARKET DRIVERS

Rising Investment in Research and Precision Medicine to Increase Demand for Metabolomics in Biomarker Discovery and Diagnostics

The rising investment in translational research and precision medicine is a driver of market growth. Many diseases, especially cancer, cardio-metabolic, and neurodegenerative diseases, are biologically diverse, limiting one-size-fits-all biomarkers and treatments. This pushes researchers to look for functional, real-time biology signals that sit closer to phenotype than genes alone. Metabolomics directly supports this need by enabling faster biomarker discovery, patient stratification, and treatment response monitoring, thereby increasing the spending on metabolomics testing, bioinformatics software, and repeat consumables across multi-site metabolomic studies and clinical translational programs. Such advantages attract co-development deals and accelerate adoption pathways.

• For instance, in February 2025, Metabolon announced new multiomics biomarker discovery functionality within its Integrated Bioinformatics Platform, positioned to make combining omics (including metabolomics) more practical for biomarker discovery and precision medicine workflows, supporting broader adoption in translational programs. Such developments are expected to drive market growth.

MARKET RESTRAINTS

High Cost Associated with Metabolomics to Hamper Market Growth

The metabolomics market growth is restrained mainly by high costs. The market cost soars as it requires high-end specialized instruments such as MS/NMR systems, which are expensive. Due to these factors, many key players delay purchases when research budgets tighten. Additionally, manual sample preparation and multi-step workflows can create variability across labs. Hence, organizations hesitate to scale metabolomics into larger, multi-site studies.

• For instance, in August 2024, EMBL reported that non-academic users were paying up to USD 140.7 per sample for untargeted metabolomics, with additional costs for sample preparation. This becomes costly for large cohorts, limiting product adoption and hampering the market's growth potential.

MARKET OPPORTUNITIES

Outsourcing Metabolomics Services to Offer Market Growth Opportunity

Outsourcing metabolomics services presents a strong market growth opportunity in the forthcoming years. Many pharmaceutical and biotechnology companies use metabolomics data but struggle to integrate it and run it in-house. Metabolomics research workflows require expensive instrumentation, strict quality controls, a trained workforce, and extensive bioinformatics for annotation and interpretation. Due to these factors, various buyers are increasingly preferring specialized CRO/service with validated workflows, scalable throughput, and experienced data teams. This reduced turnaround time offers scalability opportunities in the market. This outsourcing model also helps customers control costs and risk, access advanced expertise more quickly, and scale studies without a significant capital investment.

• For instance, in September 2025, Biognosys, a next-generation proteomics services and software company, expanded its contract research organization (CRO) services to include quantitative bio crates metabolomics and lipidomics. Such developments offer market growth opportunities.

MARKET CHALLENGES

Challenges in Inter-Laboratory Reproducibility to Hamper Market Growth

Inter-laboratory reproducibility is a major market challenge in metabolomics as results vary when different labs run the same study using different sample-prep steps, instruments, chromatography methods, calibration/QC routines, and data-processing pipelines. This variability creates batch effects and inconsistent metabolite identification and quantification. This slows timelines and reduces confidence in using metabolomics for high-stakes decisions such as clinical biomarker validation or regulated workflows. When end users cannot consistently reproduce findings across labs, they hesitate to scale metabolomics programs, which directly limits adoption and market growth.

• For instance, in November 2024, Science Direct published an article titled ‘A Reproducibility Crisis for Clinical Metabolomics Studies’ that highlighted these challenges.

Segmentation Analysis

By Offering

Products Segment Led the Market with New Product Launches by Key Players

Based on offering, the market is categorized into products, software, and services.

Among these, the products segment dominated the global metabolomics market share in 2025. Metabolomics workflows depend on high-performance, sensitive instruments such as MS/NMR systems and chromatography. Further, the recurring consumables required to run samples reliably strengthen the segment's dominance. Most labs must buy or upgrade instruments and continuously purchase columns, solvents, standards, and QC materials to keep workflows running.

Furthermore, underscoring the importance of these instruments, various key companies are directing their resources toward new product launches that align with metabolomics workflows.

• For instance, in June 2024, Waters Corporation unveiled the Xevo MRT, a benchtop mass spectrometer (MS), setting new standards for the delivery of high speed and resolution, critical for epidemiology-type and large population studies that offer complete metabolomic workflows. Such developments are expected to drive the segment's growth.

The services segment is expected to grow at a CAGR of 12.84% over the forecast period. 

To know how our report can help streamline your business, Speak to Analyst

By Technique

Advances in High Resolution Instrumentation to Drive Liquid Chromatography-Mass Spectrometry (LC-MS) Segmental Growth

Based on technique, the market is segmented into liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance spectroscopy (NMR), and others.

In 2025, the liquid chromatography-mass spectrometry (LC-MS) segment dominated the market. The high share of LC-MS is due to advances in high-resolution, intelligent instrumentation for targeted and untargeted analyses. It also fits high-throughput needs for large-scale studies, which has led to a rise in the prioritization of LC-MS upgrades by labs over others.

Additionally, new product launches in liquid chromatography further reinforce the segment's dominance.

• For instance, in June 2023, Agilent Technologies Inc., launched two new LCMS (liquid chromatography mass spectrometry) systems, the Agilent Revident LC/Q-TOF and the Agilent 6495D LC/TQ. These systems enabled high-end performance for the Revident LC/Q-TOF.

The gas chromatography-mass spectrometry (GC-MS) segment is projected to grow at a CAGR of 11.88% during the forecast period. 

By Application

Increasing Product Launches to Expand Multi-omics Studies to Propel Biomarker Discovery Segmental Growth

Based on application, the market is segmented into biomarker discovery, drug discovery, toxicology testing, precision medicine, and others.

Among these, the biomarker discovery segment dominated the market in 2025. Metabolomics is often used to detect early signals of disease biology, treatment response, and patient stratification to study real-time phenotypes. Organizations fund discovery studies to find better biomarkers, reduce downstream trial failure, and improve decision-making. Additionally, new product launches by key players to expand multi-omics studies and capabilities reinforce the segment's dominance.

• For instance, in February 2025, Metabolon, Inc., launched new multi-omics biomarker discovery capabilities within the company’s Integrated Bioinformatics Platform. This new functionality included multi-omics predictive modeling, latent factor analysis, and multi-omics pathway analysis.

In addition, the precision medicine segment is projected to grow at a CAGR of 15.15% during the analysis period.

By Disease Indication

Cancer Segment Dominated the Market owing to High Research Expenditure on Oncology

Based on disease indication, the market is segmented into cancer, cardiovascular diseases, neurological disorders, metabolic disorders, and others.

In 2025, the cancer segment dominated the market as oncology has high research spend and a high unmet clinical need. This drives the global metabolomics demand for new biomarkers for early detection, prognosis, and therapy monitoring. Cancer metabolism is highly dysregulated. Hence, metabolomics is a practical approach for identifying actionable metabolic signatures and treatment-response signals. Underscoring these advantages, many key companies are also focusing on research and development for cancer diagnostics and treatment.

• For instance, in May 2025, BioMark Diagnostics Inc., a leader in liquid biopsy tests for early cancer detection, published a study titled "M-GNN: A Graph Neural Network Framework for Lung Cancer Detection Using Metabolomics and Heterogeneous Graph Modeling,” that reported investments in AI and machine learning are supporting current studies, boosting its cancer diagnostic platform and opening new frontiers in metabolomics.

In addition, the metabolic disorder segment is projected to grow at a CAGR of 13.00% during the study period.

By End User

High Investment by Pharmaceutical and Biotechnological Companies in Research to Propel Segment Growth

Based on end user, the market is segmented into pharmaceutical and biotechnology companies, CROs/CMOs, academic & research institutes, diagnostic labs, and others.

The pharmaceutical and biotechnology companies dominate the market by end user. The large share is attributed to the substantial budgets and economic incentives to use metabolomics to improve target validation and identify toxicity signals earlier. Additionally, increasing research activities and conducting large, repeated studies increases total product spend. Strategic collaboration among these operating entities is poised to drive the growth of the segment.

• For instance, in July 2024, Evotec SE collaborated with Pfizer Inc. to focus on early discovery research for metabolic and infectious diseases. The study was carried out at the company's facility in France, which had capabilities spanning high-throughput screening, in vitro and in vivo biology, proteomics, and metabolomics.

The CROs/CMOs segment is projected to grow at a CAGR of 14.41% over the study period.

Metabolomics Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, valued at USD 0.80 billion, and maintained its leading position in 2025, with a value of USD 0.88 billion. The market in North America is expected to grow significantly over the forecast period, driven by large-scale discovery and translational programs. The region also has a dense ecosystem of CROs and specialized metabolomics service providers, which makes it easier for customers to scale studies without building everything in-house.

U.S. Metabolomics Market

Given North America’s substantial contribution and the U.S. dominance in the region, the U.S. market is estimated to touch around USD 0.88 billion in 2026, accounting for roughly 34.94% of the global market.

Europe   

Europe is projected to grow at a rate of 11.17% over the forecast period, the second-highest among all regions, and reach a valuation of USD 0.73 billion by 2026. The area is expected to experience robust growth driven by substantial public research funding and large multi-center biomedical programs.

U.K. Metabolomics market

The U.K. market is estimated to reach around USD 0.11 billion in 2026, representing roughly 4.48% of the global market.

Germany Metabolomics market

The Germany market is projected to reach approximately USD 0.19 billion in 2026, equivalent to around 7.49% of the global market.

Asia Pacific

Asia Pacific is estimated to reach a value of USD 0.73 billion in 2026 and secure the position of the third-largest region in the market. The region is witnessing expanding research infrastructure, and manufacturers are accelerating access to modern systems and application workflows.

Japan Metabolomics Market

In 2026, the Japanese market is estimated to reach around USD 0.18 billion, accounting for approximately 7.00% of the global market.

China Metabolomics Market

The China market is projected to be one of the largest worldwide, with 2026 revenues estimated to touch around USD 0.24 billion, representing approximately 9.71% of global sales.

India Metabolomics market

The India market is estimated to reach a value of around USD 0.06 billion in 2026, accounting for roughly 2.37% of global revenue.

Latin America and the Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth during the forecast period. The Latin America market is set to reach a valuation of USD 0.05 billion in 2026. The regional market growth is expanding driven by increased government support. In the Middle East & Africa, the GCC market is set to reach USD 0.03 billion in 2026.

South Africa Metabolomics Market

The South Africa market is projected to reach approximately USD 0.01 billion by 2026, accounting for roughly 0.33% of the global revenue.

COMPETITIVE LANDSCAPE

Key Industry Players

Leading Companies Focus on Strategic Collaborations and Pipelines to Expand Market Share

The global metabolomics market is highly consolidated, with companies such as Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Waters Corporation, Bruker Corporation, and Metabolon holding a significant market share. Strategic partnerships, expanding pipelines, technological advancements, and increased investments in the sector drive these companies' market share.

• For instance, in July 2025, Bruker Corporation acquired biocrates life sciences AG, a leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide.

Such developments are likely to propel market growth. Other notable companies in the global market comprise Merck KGaA, Panome Bio, and Bio-Rad Laboratories, Inc. These players are anticipated to prioritize strategic partnerships, technological advancements, and new product launches to consolidate their position during the forecast period.

LIST OF KEY METABOLOMICS COMPANIES PROFILED

• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• DH Life Sciences, LLC. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Bruker Corporation (U.S.)
• Waters Corporation(U.S.)
• Shimadzu Corporation (Japan)
• Trinity Biotech (Ireland)
• Bio-Rad Laboratories, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

• September 2025: Panome Bio launched a metabolomics workflow for formalin-fixed, paraffin-embedded (FFPE) samples, expanding access to discovery metabolomics for clinical and translational research.
• April 2025: Metabolon, Inc., launched a comprehensive new microbiome research solution that integrated metagenomics sequencing and bioinformatics tools with a microbiome metabolite panel to create a powerful microbiome research toolkit.
• March 2025: Linearis inaugurated its laboratory and high-throughput metabolomics platform, integrating AI (artificial intelligence) to accelerate benefits to patients and support life sciences projects.
• September 2024: Trinity Biotech plc acquired Metabolomics Diagnostics, a leading provider of biomarker-based diagnostic solutions. This acquisition provides Trinity Biotech with a deep-tech platform combining mass spectrometry with machine learning-powered bioinformatics.
• November 2023: Trajan Scientific Australia Pty Ltd launched a new method for the analysis of blood microsamples in metabolomics research deployed Trajan’s Mitra device, based on VAMS technology, which is anticipated to enable advancements in the field. Scientists at Metabolon, Inc., a leader in metabolomics solutions that advance a range of life science studies, validated the bioanalytical method.

REPORT COVERAGE

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation